Form 4: Viridian Therapeutics, Inc.\DE Executive Sells Shares

Sentiment:

Insider Transaction (Form 4)


Jennifer Tousignant, Chief Legal Officer of Viridian Therapeutics, Inc.\DE, sold 14,212 shares of common stock on August 19, 2026 for $24.50 per share.

Summary

  • Open-market sale: disposed of 4,212 Common Stock at $24.50 ($103,194) on August 19, 2026 (Direct).
  • Option exercise/conversion: acquired 10,000 Common Stock at $14.41 ($144,100) on August 19, 2026; holds 10,000 after (Direct).
  • Open-market sale: disposed of 10,000 Common Stock at $24.50 ($245,000) on August 19, 2026 (Direct).
  • Option exercise/conversion: disposed of 10,000 Stock Option (Right to Buy) on August 19, 2026; holds 114,072 after (Direct).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative signal: an insider sold $348,194 of stock on the open market.

Insider Transactions

Jennifer Tousignant — Officer (Chief Legal Officer)

DateTransactionSecuritySharesPriceValueHeld After
2026-08-19Open-market saleCommon Stock4,212$25$103.2K0
2026-08-19Option exercise/conversionCommon Stock10,000$14$144.1K10,000
2026-08-19Open-market saleCommon Stock10,000$25$245.0K0
2026-08-19Option exercise/conversionStock Option (Right to Buy)10,000——114,072

Key Dates

DateDescription
2026-08-19Open-market sale (4,212 shares)
2026-08-19Option exercise/conversion (10,000 shares)
2026-08-19Open-market sale (10,000 shares)
2026-08-19Option exercise/conversion (10,000 shares)

Keywords

insider transaction, Form 4, VRDN, Viridian Therapeutics, Inc.\DE, bearish, Jennifer Tousignant

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.